Critical Review: Rocket One Inc. Common Stock (NASDAQ:RKTO) versus Lasertec (OTCMKTS:LSRCY)

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Lasertec (OTCMKTS:LSRCY) are both technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rocket One Inc. Common Stock and Lasertec, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1	0	1	0	2.00
Lasertec	0	0	0	1	4.00

Rocket One Inc. Common Stock presently has a consensus target price of $5.00, suggesting a potential upside of 528.61%. Given Rocket One Inc. Common Stock’s higher probable upside, equities analysts clearly believe Rocket One Inc. Common Stock is more favorable than Lasertec.

Earnings and Valuation

This table compares Rocket One Inc. Common Stock and Lasertec”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47 million	($0.80)	-0.99
Lasertec	N/A	N/A	N/A	N/A	N/A

Insider & Institutional Ownership

7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Rocket One Inc. Common Stock and Lasertec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Lasertec	N/A	N/A	N/A

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

About Lasertec

Lasertec Corporation engages in the designing, manufacturing, and sale of inspection and measurement equipment in Japan and internationally. The company offers semiconductor related products, which includes mask related systems for extreme ultraviolet and deep ultraviolet solutions, and wafers inspection and review systems; and FPD photomask inspection systems. It also provides laser microscopes, electro-chemical reaction visualizing confocal, and coating thickness scanning system; and in-situ observation at ultra high temperature confocal scanning laser microscope. The company was formerly known as NJS Corporation and changed its name to Lasertec Corporation in 1986. Lasertec Corporation was founded in 1960 and is headquartered in Yokohama, Japan.